连亏10年的泽璟制药控股股东拟减持 A股两募资共32亿

Core Viewpoint - ZaiJing Pharmaceutical (688266.SH) announced a share reduction plan by major shareholders, including Chairman Zelin Sheng and Ningbo Zeao Venture Capital, due to personal funding needs, which will not affect the company's governance structure or control [1][2]. Share Reduction Plan - Zelin Sheng plans to reduce his holdings by up to 273,907 shares, representing 0.1035% of the total share capital, while Ningbo Zeao intends to reduce up to 2,475,090 shares, or 0.9350% of the total share capital [1]. - The reduction period is set for three months starting 15 trading days after the announcement, with prices determined by market conditions at the time of sale [1]. - The estimated cash proceeds from Zelin Sheng's reduction are approximately 25.86 million yuan, while Ningbo Zeao's are about 233.70 million yuan, totaling around 259.56 million yuan [1]. Shareholding Structure - As of the announcement date, Zelin Sheng holds 49,910,527 shares (18.85% of total shares), while his associate, Lu Huiping, holds 12,631,644 shares (4.77% of total shares), bringing their combined holdings to 62,542,171 shares (23.63% of total shares) [2]. - Ningbo Zeao holds 16,500,600 shares (6.23% of total shares) [2]. Financial Performance Forecast - ZaiJing Pharmaceutical forecasts 2025 revenue between 796.49 million yuan and 828.99 million yuan, representing a year-on-year increase of 49.45% to 55.55% [3]. - The company expects a net loss attributable to shareholders of between 191.39 million yuan and 139.60 million yuan, indicating an increase in losses compared to the previous year [3]. - Historical net profits from 2016 to 2024 show consistent losses, with the most recent loss reported at 138 million yuan [3]. Fundraising and Financials - The company raised a total of 202.56 million yuan from its initial public offering, with a net amount of 190.82 million yuan after expenses [4]. - The final net amount raised was less than the original plan by 47.57 million yuan, with funds allocated for new drug development and operational reserves [4]. - ZaiJing Pharmaceutical has raised a total of 322.56 million yuan since its listing [5].